Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408184 | 0.78 | CA4 (0.61) | KMT2A | |
| SCHEMBL1220588 | 0.64 | CA4 (0.65) | NPC1KMT2ARAB9A | |
| SCHEMBL14980286 | 0.64 | CA4 (0.65) | KMT2A | |
| SCHEMBL1220300 | 0.63 | CA4 (0.48) | NPC1 | |
| SCHEMBL1746427 | 0.63 | CA4 (0.48) | NPC1 | |
| SCHEMBL16558090 | 0.63 | BUB1 (0.51) | KMT2A | |
| SCHEMBL1746019 | 0.61 | CA2 (0.47) | NPC1 | |
| SCHEMBL21172119 | 0.61 | CA4 (0.61) | KMT2A | |
| SCHEMBL10031827 | 0.61 | PGR (0.47) | — | |
| SCHEMBL26054401 | 0.59 | MAPT (0.58) | NPC1KMT2ATDP1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072793-B2 | DsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190169611-A1 | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | LMNA, LMNB2, LMNB1 | NPC1 457/4885KMT2A 2685/4885TDP1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.